Treatment Options in COVID-19: The Role of Bioavailable Antiviral Ribonucleoside Analog on NHC in Vitro
Journal Title: Journal of Regenerative Biology and Medicine - Year 2020, Vol 2, Issue 2
Abstract
On December 31, 2019, WHO was informed of cases of pneumonia of unknown cause in Wuhan City, China. A novel coronavirus was identified as the cause by Chinese authorities on January 7, 2020 and was provisionally named "2019-nCoV". This new Coronavirus causes a clinical picture which has received now the name COVID-19. The virus has spread subsequently worldwide and was explained on the 11th of March, 2020 by the World Health Organization to the pandemic. There is no admitted therapy for COVID-19, and the present standard of treatment is the supporting treatment. SARS CoV 2 uses the cell entry receptor protein to Angiotensin-Converting enzyme II (ACE-2) to reach human cells and to infect [2]. What we know is that SARS-CoV-2 needs for entry in the cell (Pneumocytes II) the help of a serine protease TMPRSS2 and cathepsin L [2-4]. Since the outbreak in China in December 2019 researchers searching for adequate therapy to control viral spreading and to inhibit COVID-19 effectively. To date, no effective drug to treat this severe viral infection was found. Publications about angiotensin II receptor blocker reveal a new effective method to think about in treating COVID-19 [6-10]. Moreover, different therapy options were started to stop the devastating potential of COVID-19 worldwide. Antibody-rich donated plasma from survivors, different inhibitors are part of analysis to stop the entry of the virus into the cell and disturb the connection between SARS-CoV-2 and angiotensin-2 receptor binding. A new orally bioavailable broad-spectrum antiviral inhibits was found in SARS CoV-2 in human airway epithelial cell structures and in different coronaviruses in mice and published in SCIENCE [5]. In this publication, the ribonucleoside analog beta-D-N4-hydroxycytidine (NHC, EIDD 1931) had great potential and antiviral potency against SARS-CoV-2. The results of Timothy Sheahan`s work and his colleagues highlight the potential utility as an effective antiviral drug against COVID-19 corona virus in vitro [5]. As a consequence, further off-label trials in severe COVID-19 patients must follow.
Authors and Affiliations
Stefan Bittmann, Anne Weissenstein, Gloria Villalon, Elena Moschüring-Alieva, Lara Bittmann and Elisabeth Luchter
Keywords
Related Articles
- EP ID EP707326
- DOI https://doi.org/10.37191/Mapsci-2582-385X-2(1)-024
- Views 80
- Downloads 0
Overview of Current Regulatory Practices, Challenges and Guidance for Regulation of Stem Cells and Stem Cell Derived Products in India
Stem Cell Science/Regenerative Medicine is perhaps the most important "pillar" out of the four pillars of modern medicine. Use and abuse of the "Stem Cells and Stem Cell derived Products" as therapeutic measure for treat...
Bioethics Human Papillomavirus and HPV Vaccine
This paper will discuss what the Human Papillomavirus (HPV) is. Ethical questions posed are “Should the HPV (Human Papillomavirus) vaccine be required? If yes at what age and should it be required for both boys and g...
HGH and Cartilage
Recombinant human growth hormone (rHGH) which plays an important role for remodeling of bone has an effect on cartilage differentiation and regeneration, as well. Herein, we reviewed human growth hormone and its roles on...
Aberfan: In memoriam
It was an ordinary day in Aberfan, Wales, and it ended in a disaster. On October 21, 1966, a 34-meter-high slag heap broke loose, slid down Mount Merthyr into the mining village and buried houses and an elementary school...
Relentless Regeneration
Regenerative Medicine is a branch of medicine holding promise for the repair of cells, tissues, and organs to effective function. Much of the field has been developed in response to damage sustained by injury and disease...